Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Uveal Melanoma 1Uterine Cervical Neoplasms 1Solid Tumors, Adult 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma 1Bronchial Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 9Pemetrexed 7pembrolizumab 4osimertinib 3entinostat 3Gemcitabine 3zipalertinib 2selpercatinib 2pralsetinib 2durvalumab 2camrelizumab 2Paclitaxel 2Erlotinib Hydrochloride 2Cisplatin 2Bronchoscopy 2taletrectinib 1sotorasib 1repotrectinib 1patritumab 1necitumumab 1ficlatuzumab 1exemestane 1demcizumab 1cobimetinib 1ceralasertib 1atezolizumab 1alectinib 1aflibercept 1Vinorelbine 1Toll-Like Receptor 1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lung Diseases × Toll-Like Receptor 1 × Clear all
NCT04614103 2026-04-15

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
170 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡